Pcn131 - Assessing the Real-World Cost of Care in Patients With Metastatic Triple Negative Breast Cancer (Mtnbc) in the United States

Abstract

OBJECTIVES: The recent approval of novel immuno-oncology (IO) therapies has altered the standard of care for patients with metastatic MCC. The objective of this study was to evaluate treatment patterns and associated healthcare costs among patients with newly diagnosed MCC. METHODS: Patients with newly diagnosed MCC were identified by between July 2010 and December 2014 in MarketScan administrative claims databases. Per-patient per-year (PPPY) costs were estimated and adjusted to 2017 US dollars. RESULTS: 2355 patients met the selection criteria with requisite continuous plan enrolment 6 months before the index date, defined as the first occurrence of a medical claim for an eligible ICD-9 code, of whom 2177 had no enrolment gap 30 days during follow-up. The mean age at diagnosis was 68.8 years; 60.3% were male. In the post-index period, surgery alone was the most common treatment (34.5%), followed by a combination of surgery and radiation (22.0%) and triple therapy with surgery, radiation, and chemotherapy (14.7%). Overall, 27.5% received chemotherapy, and 14.5% did not receive any treatment. The highest total costs PPPY were observed in patients receiving chemotherapy alone (mean, $154,506; median, $101,487) and in those receiving chemotherapy and radiation (mean, $150,157; median, $129,041). The lowest healthcare PPPY costs were incurred by patients who only underwent surgery (mean, $56,124; median, $22,999) and by those who did not receive any treatment (mean, $28,442; median, $8998). CONCLUSIONS: These results provide useful insights into real-world treatment patterns of patients with newly diagnosed MCC. Costs of managing MCC are high irrespective of the type of treatment received. The use of chemotherapy potentially indicates greater disease severity and increasing burden on healthcare resources. Further analyses will facilitate better understanding of the value of IO therapy in treating this mainly elderly patient population and alleviating the associated economic burden.

Naturally occurring deamidated triosephosphate isomerase is a promising target for cell-selective therapy in cancer

“…Since these drugs are directed to targets (mainly nucleic acids and the replication machinery) present in both cancer and normal cells, the side effects of such treatments are considerable and usually severe. Additionally, their economic burden has a great impact on patients suffering from this disease 40 . In contrast, our strategy would represent a safer and less expensive therapy for this kind of cancer.…”

Deamidated TPI is an efficacious target for cell-selective therapy in triple-negative breast cancer

“…Additionally, their economic burden has a significant impact on patients suffering from this disease [39]. In contrast, our strategy would represent a safer and less expensive therapy for this kind of cancer.…”